- First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless.Rebecca Dresser - 2009 - Journal of Law, Medicine and Ethics 37 (1):38-50.details
|
|
Genetic Research as Therapy: Implications of "Gene Therapy" for Informed Consent.Larry R. Churchill, Myra L. Collins, Nancy M. R. King, Stephen G. Pemberton & Keith A. Wailoo - 1998 - Journal of Law, Medicine and Ethics 26 (1):38-47.details
|
|
Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.Jonathan Kimmelman & Alex John London - unknowndetails
|
|
Genetic Research as Therapy: Implications of "Gene Therapy" for Informed Consent.Larry R. Churchill, Myra L. Collins, Nancy M. R. King, Stephen G. Pemberton & Keith A. Wailoo - 1998 - Journal of Law, Medicine and Ethics 26 (1):38-47.details
|
|
Ethical responsibilities of nanotechnology researchers: A short guide. [REVIEW]Robert McGinn - 2010 - NanoEthics 4 (1):1-12.details
|
|
Defining and Describing Benefit Appropriately in Clinical Trials.Nancy M. P. King - 2000 - Journal of Law, Medicine and Ethics 28 (4):332-343.details
|
|
Consent forms and the therapeutic misconception.Nancy M. P. King, Gail E. Henderson, Larry R. Churchill, Arlene M. Davis, Sara Chandros Hull, Daniel K. Nelson, P. Christy Parham-Vetter, Barbra Bluestone Rothschild, Michele M. Easter & Benjamin S. Wilfond - 2005 - IRB: Ethics & Human Research 27 (1):1-7.details
|
|
Missing the Forest: Further Thoughts on the Ethics of Bystander Risk in Medical Research.Jonathan Kimmelman - 2007 - Cambridge Quarterly of Healthcare Ethics 16 (4):483.details
|
|
Misunderstanding in Clinical Research: Distinguishing Therapeutic Misconception, Therapeutic Misestimation, & Therapeutic Optimism.Sam Horng & Christine Grady - 2003 - IRB: Ethics & Human Research 25 (1):11.details
|
|
The Challenge of Incidental Findings.Susan M. Wolf - 2008 - Journal of Law, Medicine and Ethics 36 (2):216-218.details
|
|
Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field.Leili Fatehi, Susan M. Wolf, Jeffrey McCullough, Ralph Hall, Frances Lawrenz, Jeffrey P. Kahn, Cortney Jones, Stephen A. Campbell, Rebecca S. Dresser, Arthur G. Erdman, Christy L. Haynes, Robert A. Hoerr, Linda F. Hogle, Moira A. Keane, George Khushf, Nancy M. P. King, Efrosini Kokkoli, Gary Marchant, Andrew D. Maynard, Martin Philbert, Gurumurthy Ramachandran, Ronald A. Siegel & Samuel Wickline - 2012 - Journal of Law, Medicine and Ethics 40 (4):716-750.details
|
|
First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless.Rebecca Dresser - 2009 - Journal of Law, Medicine and Ethics 37 (1):38-50.details
|
|
Genetic Research as Therapy: Implications of “Gene Therapy” for Informed Consent.Larry R. Churchill, Myra L. Collins, Nancy M. P. King, Stephen G. Pemberton & Keith A. Wailoo - 1998 - Journal of Law, Medicine and Ethics 26 (1):38-47.details
|
|
Assessing Benefits in Clinical Research: Why Diversity in Benefit Assessment Can Be Risky.Larry R. Churchill, Daniel K. Nelson, Gail E. Henderson, Nancy M. P. King, Arlene M. Davis, Erin Leahey & Benjamin S. Wilfond - 2003 - IRB: Ethics & Human Research 25 (3):1.details
|
|